Affibody granted Algeta exclusive, worldwide rights to two carrier molecules targeting EGFR2 and PDGFRB

Affibody AB

Sweden / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Algeta ASA

Norway / Mid-Cap Biopharma ($1-$50 billion)

$1,069.8m on 05/13/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced